Biological Assessment in Dental Practice Relevance and Interpretation

01

FBC — Red Cell Line and Anaemia Management

The full blood count (FBC) — a cornerstone of clinical decision-making

The FBC provides a panoramic view of the three cell lineages — erythrocytes, leucocytes and platelets — supplying crucial indices on oxygen-carrying capacity, immune defence status and primary haemostatic integrity.

Anaemia is biologically defined by a haemoglobin below 13 g/dL in men and 12 g/dL in women. Inadequate tissue oxygenation in peri-implant or post-extraction sites predisposes to necrotic complications and secondary infection.

Erythrocyte parameters — Normal values and dental implications

Parameter	Normal values (adult)	Dental implications
Haemoglobin (Hb)	M: 13–17 g/dL · F: 12–16 g/dL	Risk of defective healing if < 10 g/dL
Haematocrit (Hct)	M: 40–52% · F: 37–47%	Reflects blood viscosity and O₂ transport capacity
MCV	80–100 fL	Microcytosis (iron deficiency) or Macrocytosis (B₁₂ deficiency)
Reticulocytes	25,000–100,000/mm³	Bone marrow capacity to respond to blood loss

Microcytosis (MCV < 80 fL)

Iron deficiency anaemia — the most common cause

Oral signs: atrophic glossitis, angular cheilitis
Pallor of oral mucous membranes
Risk of delayed healing after extraction
Investigate underlying cause: occult bleeding, malabsorption

Macrocytosis (MCV > 100 fL)

B₁₂/folate deficiency — chronic alcohol use frequently implicated

Hunter's glossitis (smooth, red, painful tongue)
Recurrent aphthous ulcerations
Alert to possible associated haemostatic disorders
In chronic alcoholism: elevated risk of concurrent hepatic impairment

Critical threshold — Haemoglobin < 10 g/dL A haemoglobin level below 10 g/dL generally requires deferral of non-urgent invasive surgical procedures. Intraoperative tissue hypoxia substantially raises the risk of necrosis and postoperative secondary infection. Prior correction in liaison with the treating physician is necessary.

02

FBC — White Cell Line and Infectious Vigilance

Leucocytes — sentinels of oral immunity

Leucocytes play a fundamental protective role against endodontic and periodontal infections. Their normal count ranges between 4,000 and 10,000/mm³. Leucocytosis (> 11,000/mm³) is frequently reactive to an acute bacterial infection (perimaxillary cellulitis, periodontal abscess). Neutrophilia (> 7,500/mm³) generally confirms a bacterial origin.

Neutropenia decision thresholds for oral surgery

Category	Neutrophils/mm³	Management approach
Normal	1,500 – 7,500	Oral surgery according to standard protocols
Mild neutropenia	1,000 – 1,500	Heightened vigilance — strict oral hygiene
Moderate neutropenia	500 – 1,000	Antibiotic prophylaxis usually required for any invasive procedure
Agranulocytosis	< 500	Formal contraindication to outpatient care — multidisciplinary hospital setting required

Lymphopenia (< 1,500/mm³) and HIV — CD4+ count mandatory Lymphopenia is often the biological marker of acquired immunosuppression (HIV). The workup must be completed with a CD4+ lymphocyte count. CD4 < 200/mm³ classifies the patient as AIDS-stage: high risk of opportunistic infections and surgical complications. Systematic antibiotic prophylaxis is required for any invasive procedure.

03

FBC — Platelets and Primary Haemostasis

Platelets — normal value: 150,000 to 400,000/mm³

Thrombocytopenia is the most frequent cause of prolonged bleeding or unexplained gingival haemorrhage in the dental practice. Clinical management follows precise decision thresholds.

1

> 100,000/mm³

Oral surgery may be carried out according to standard protocols.

No enhanced haemostatic measures beyond the routine protocol required.

2

50,000 – 100,000/mm³

Procedure feasible in a dental office but requiring enhanced local haemostasis: compressive sutures, biological glues, absorbable haemostatic sponges.

Prolonged compression for at least 10 minutes.

3

< 50,000/mm³

Critical risk of spontaneous or provoked haemorrhage. Hospital setting mandatory, usually after platelet concentrate transfusion 30 minutes before the procedure.

!

Thrombocytosis > 500,000/mm³

Can paradoxically cause bleeding (clotting factor consumption) or increase thromboembolic risk.

Haematology consultation before any procedure.

04

Coagulation Screen — INR, APTT, DOACs and Antiplatelets

INR and patients on vitamin K antagonists (VKAs)

The PT (70–130% normal) assesses the extrinsic coagulation pathway. For patients on warfarin or acenocoumarol, the INR is the universal monitoring tool. Management has radically changed: it is now formally recommended to not discontinue treatment for low or moderate haemorrhagic risk procedures.

!

INR — The golden rule for oral surgery under VKA therapy

Stable INR < 4 — Procedure safe to proceed

The procedure is safe if the INR, measured within the 24 hours preceding the procedure, is stable and below 4. Maintain the VKA + reinforced local haemostasis.

INR > 4 — Defer and alert

INR > 4 signals overdosage. Defer the procedure and inform the prescribing physician for dose correction. Never autonomously discontinue a VKA.

Summary table — Safety thresholds for oral surgery

Biological test	Normal value	Safety threshold for oral surgery
INR (under VKA)	2.0 – 3.0 (therapeutic)	< 4 (stability required)
Platelets	150 – 400 G/L	> 50 G/L (local haemostasis)
PT	> 70%	> 30% (specialist setting if < 30%)
APTT (ratio)	< 1.2	Prolongation > 10 s = major caution
Fibrinogen	2 – 4 g/L	> 1 g/L to ensure clot formation

Direct oral anticoagulants (DOACs)

Rivaroxaban, Apixaban, Dabigatran — limited biological monitoring

Do not reliably or predictably alter PT or APTT
Specific anti-Xa assays not recommended routinely for minor oral surgery
Strategy: maintain therapy + schedule the procedure at trough plasma concentration (just before the next dose)

Antiplatelet agents (APAs)

Aspirin, Clopidogrel — SFCO / HAS recommendations

Bleeding time (BT) is no longer a reliable predictive test — do not prescribe routinely
Single-agent therapy must be maintained for conventional oral surgery
Dual antiplatelet therapy (Aspirin + Clopidogrel after stenting): cardiologist opinion mandatory

05

HbA1c and Diabetes — Dental Implications

The bidirectional diabetes-periodontitis relationship — established scientific fact

Glycaemic imbalance impairs immune response and collagen synthesis, aggravating periodontal destruction. Conversely, chronic periodontal inflammation perpetuates insulin resistance. HbA1c — reflecting glycaemic balance over the preceding 120 days — is the reference marker for therapeutic decision-making.

Decision table — HbA1c and surgical management

HbA1c	Glycaemic status	Dental management approach
< 7%	Well-controlled diabetes	Care without systematic antibiotic prophylaxis — risk comparable to healthy subject
7 – 8%	Precarious control	Heightened vigilance — intensive oral hygiene motivation and optimal plaque control
8 – 10%	Moderate imbalance	Antibiotic prophylaxis recommended (Amoxicillin 2 g 1 h before) for invasive procedures
> 10%	Severe imbalance	Defer non-urgent invasive procedures — prior metabolic improvement mandatory

Periodontal staging and HbA1c — Automatic Grade C when > 7% Current periodontal classifications incorporate HbA1c as a "grading" factor. A diabetic patient with HbA1c > 7% is automatically classified as Grade C (rapid progression), fundamentally altering prognosis and follow-up frequency. In implantology, the risk of early peri-implantitis directly correlates with HbA1c levels.

06

Renal Function — eGFR and Prescribing Adaptations

Estimated glomerular filtration rate (eGFR) — the reference indicator

Serum creatinine alone is not a reliable indicator (influenced by age, sex and muscle mass). eGFR estimation via the MDRD or CKD-EPI formula is now the indispensable standard for adapting dental prescriptions.

Chronic kidney disease stages and therapeutic approach

CKD stage	eGFR (mL/min/1.73 m²)	Therapeutic approach
Normal	> 90	Standard prescribing
Mild impairment	60 – 89	Monitoring — avoid prolonged NSAID courses
Moderate impairment	30 – 59	Amoxicillin dose adjustment — NSAIDs formally contraindicated
Severe impairment	15 – 29	Strict dose adaptation — medical advice mandatory
End-stage renal disease	< 15	Dialysis — specific post-dialysis prescribing protocols

NSAIDs and renal impairment — Formal contraindication from CKD Stage 3 (eGFR < 60) NSAIDs (ibuprofen, naproxen) inhibit synthesis of the renal prostaglandins essential to maintaining glomerular perfusion. From CKD Stage 3 onwards, they risk precipitating acute kidney injury on chronic kidney disease. Paracetamol (acetaminophen) remains the first-line analgesic (max 3 g/day in moderate CKD).

Amoxicillin dose adjustment according to eGFR

When eGFR is between 10 and 50 mL/min: the dose must be reduced or the dosing interval extended (1 g every 12 hours instead of every 8 hours). Below 10 mL/min: nephrology consultation before any prescription.

07

Hepatic Function — Drug Metabolism

Liver function panel — ALT, AST, GGT, Bilirubin

Cytolysis and cholestasis — prescribing precautions

Elevated transaminases (cytolysis) → caution with high first-pass hepatic drugs
Elevated GGT in alcoholism → alert to associated coagulopathy risk (low PT)
Elevated bilirubin → significant hepatitis or cholestasis
Elevated ALP → cholestasis or bone pathology

Paracetamol and hepatotoxicity

The reference analgesic — unless doses are exceeded

Limit to 2 g/day maximum in cirrhotic or malnourished patients (glutathione stores depleted)
The toxic metabolite NAPQI accumulates and causes hepatic necrosis even at therapeutic doses
Metronidazole and some macrolides: monitoring or adjustment required in severe hepatic impairment
NSAIDs: use with extreme caution or avoid in decompensated cirrhosis

08

CRP and ESR — Orofacial Infection Biomarkers

C-reactive protein (CRP) — the gold standard for monitoring odontogenic infections

CRP is an acute-phase protein with rapid kinetics: it rises 4 to 6 hours after infection onset (half-life: 5–7 hours). It is the ideal tool for monitoring therapeutic efficacy in orofacial infections of dental origin.

1

Assessing initial severity

CRP > 50–100 mg/L is strongly correlated with spread of infection to the fascial spaces and predicts a risk of prolonged hospitalisation.

2

Monitoring treatment response

Rapid decline after surgical drainage and antibiotherapy confirms efficacy.

Absent drop at Day 2–3 post-op: suspect bacterial resistance or undrained focus.

!

Very high ESR (> 100 mm/1st hour)

Never dismiss. May reveal a serious underlying pathology: multiple myeloma, giant cell arteritis (Horton), active neoplasia.

Refer for further investigation.

3

Perspectives — Combined CRP-NLR

Combined inflammatory indices (CRP + neutrophil-to-lymphocyte ratio) open prospects for high-precision predictive oral medicine.

09

HAS 2024 — Infective Endocarditis and Pre-Implant Workup

Infective endocarditis — 40% 5-year mortality, ~20% of oral origin

IE remains a gravely serious disease. The HAS 2024 recommendations have simplified the classification of at-risk patients and broadened the therapeutic options previously contraindicated (root canal treatment, implantology under conditions).

Major HAS 2024 change — Clindamycin no longer recommended as first-line AP In patients with beta-lactam allergy, clindamycin is abandoned as a first-line antibiotic prophylaxis alternative due to the risk of Clostridium difficile pseudomembranous colitis. It is replaced by: Azithromycin 500 mg, clarithromycin, or cefalexin (if penicillin allergy is not immediate-type).

High-risk patients — Antibiotic prophylaxis mandatory

Prosthetic valves · Cyanotic congenital heart disease · History of IE

Antibiotic prophylaxis (AP) mandatory for any invasive procedure inducing bacteraemia
Protocol: Amoxicillin 2 g PO 30–60 minutes before the procedure
Immediate penicillin allergy: Azithromycin 500 mg or Clarithromycin
Emphasis on the "non-pharmacological component": impeccable oral hygiene + systematic eradication of infectious foci before valve surgery

Pre-implant biological workup — HAS 2024

Systematic preoperative assessment

HbA1c less than 3 months old for any diabetic patient
Renal function workup in polymedicated or elderly patients
Verified absence of infectious foci via clinical examination + OPG
Complete ASA classification before any complex rehabilitation plan

10

Specific Contexts — HIV and Chemotherapy

HIV and immunosuppression — Surgical planning

CD4+ count and viral load — the two biological pillars

CD4 > 500/mm³: conventional management feasible
CD4 200–500/mm³: heightened vigilance, antibiotic prophylaxis to be discussed
CD4 < 200/mm³ (AIDS stage): systematic antibiotic prophylaxis + close platelet monitoring (thrombocytopenia frequent)
Undetectable viral load on ARV therapy = marker of good treatment adherence

Chemotherapy — Dental management by FBC status

Nadir period — Days 7 to 14 post-cycle

Comprehensive dental assessment mandatory before cervicofacial radiotherapy (prevents osteoradionecrosis)
Invasive procedures to avoid during nadir (maximal leucocyte and platelet drop, Days 7–14)
Verify FBC before each scheduled procedure during treatment
Systematic coordination with the oncology team

11

Clinical FAQ

No. Current SFCO and HAS recommendations are unambiguous: VKAs (warfarin, acenocoumarol) must not be discontinued for low or moderate haemorrhagic risk procedures (single extractions, scaling, root planing, implant placement without risk factors). Interrupting treatment exposes the patient to a potentially life-threatening thrombotic risk (stroke, pulmonary embolism, prosthetic valve thrombosis). The safe strategy relies on: (1) INR measurement within the 24 hours preceding the procedure — intervention is safe if the INR is stable and < 4; (2) reinforced local haemostasis (sutures, biological adhesives, absorbable sponges, 10-minute compression); (3) patient education and tranexamic acid mouthwash prescription if needed.

No. Bleeding time is no longer a reliable predictive test for intraoperative haemorrhagic risk and should not be routinely prescribed. SFCO and HAS recommendations are clear on this point. Its inter-operator variability and weak positive predictive value render it an obsolete test for daily practice. Haemorrhagic risk assessment now relies on a rigorous medication history (VKAs, DOACs, APAs, LMWH), a personal and family haemorrhagic history, and — when clinically indicated — a targeted workup (platelet count, INR, APTT) based on the specific clinical context.

Current literature and HAS 2024 recommendations suggest that an HbA1c below 7–8% is the generally accepted threshold for implantology under acceptable safety conditions. Above 8%, the risk of early peri-implantitis, failed osseointegration and postoperative infectious complications rises significantly. Between 7% and 8%, implant placement remains feasible with systematic antibiotic prophylaxis, enhanced plaque control and close follow-up. Above 10%, implantology should be deferred until metabolic control has improved under the endocrinologist or treating physician. A result less than 3 months old is required per HAS 2024 recommendations.

No, from CKD Stage 3 (eGFR < 60 mL/min). NSAIDs — including ibuprofen and naproxen — are formally contraindicated from this stage, as they inhibit synthesis of the renal prostaglandins essential to maintaining glomerular perfusion, risking acute-on-chronic kidney injury. For dental pain relief in CKD: paracetamol (acetaminophen) remains the first-line option (maximum 3 g/day in moderate CKD, 2 g/day in severe CKD). Codeine and tramadol should be used cautiously at reduced doses. If ibuprofen is being considered for a patient of unknown renal function, a recent eGFR must be checked before prescribing.

The septic emergency must always be addressed, but the protocol depends on the patient's current biological status. Before any procedure, a recent FBC is essential (ideally < 48 hours). If we are outside the nadir (leucocytes > 2,000/mm³ and platelets > 50,000/mm³), conservative surgical drainage may be performed with systematic antibiotic prophylaxis. If the patient is in the nadir period (Days 7–14), systemic infection risk is at its peak: the patient must be urgently referred to hospital emergency services for multidisciplinary management with the haematology-oncology team. A probabilistic antibiotic as a bridge may be started, but the decision to perform an invasive procedure during nadir belongs to the hospital medical team, not to the outpatient dental practice.

No. On single-agent aspirin therapy (or any other antiplatelet agent alone), current recommendations (SFCO, HAS) call for maintaining treatment for conventional oral surgery, including extractions and periodontal procedures. The cardiovascular risk associated with stopping aspirin (thrombotic rebound, risk of myocardial infarction or ischaemic stroke, particularly after coronary stent placement) far exceeds the dental haemorrhagic risk, which is manageable through local haemostatic measures. The situation becomes more complex with dual antiplatelet therapy (aspirin + clopidogrel or ticagrelor) after coronary stent placement: in this case, cardiologist opinion is mandatory before any decision to modify treatment.

Ref

References

Clinical guidelines and recommendations

1

HAS 2024 Haute Autorité de Santé (HAS). Oral and dental management of patients at high risk of infective endocarditis 2024 — updated recommendations.
has-sante.fr — Infective endocarditis 2024
2

SFCO French Society of Oral Surgery (SFCO). Recommendations for the management of patients on vitamin K antagonist therapy in oral surgery.
societechirorale.com — VKA patients in oral surgery
3

HAS HAS. Implant-prosthetic management of edentulism — preoperative biological workup.
has-sante.fr — Implantology and biological workup
4

SFCO SFCO / HAS. Perioperative management of patients on antithrombotic therapy in oral surgery.
societechirorale.com — Antithrombotics in oral surgery

Diabetes, periodontology and implantology

5

Study Preoperative HbA1c and Blood Glucose Measurements in Diabetes Mellitus before Oral Surgery and Implantology Treatments. MDPI / PMC.
pmc.ncbi.nlm.nih.gov — HbA1c and oral surgery
6

Review Interrelationships between periodontal treatment and chronic conditions. UFSBD.
ufsbd.fr — Periodontitis and systemic disease

CRP and orofacial infections

7

Pooled analysis Efficacy of serum CRP levels as monitoring tools for patients with fascial space infections of odontogenic origin. PMC.
pmc.ncbi.nlm.nih.gov — CRP and odontogenic fascial infections
8

Review The Role of C-Reactive Protein and Neutrophil to Lymphocyte Ratio in Predicting the Severity of Odontogenic Infections. PMC / ResearchGate.
pmc.ncbi.nlm.nih.gov — CRP-NLR and odontogenic infections

Renal and hepatic function — Drug prescribing

9

HAS HAS. Serum creatinine measurement — eGFR estimation and early CKD diagnosis.
has-sante.fr — eGFR and chronic kidney disease
10

Review Drug prescribing in dentistry and chronic kidney disease. SDS News.
sds-news.com — Dental prescriptions and CKD
11

Review Drug use in the cirrhotic patient. CBIP.
cbip.be — Drugs and liver cirrhosis
12

Review Biological assessment in oral and dental medicine — relevance and interpretation. AOS / EDP Sciences.
aos.edpsciences.org — Biological assessment in dentistry